

**REMARKS**

With entry of this amendment, claims 1, 5-13 and 16-17 are pending. The claims have been amended to more particularly recite specific embodiments of the invention. Claim 1 has been amended to include limitations of Claims 2-4, which are cancelled. Claim 13 has been similarly amended. Claim 17 replaces claim 14, and recites active steps. No new matter has been added. Reconsideration is requested.

The Examiner objected to the specification because the trademark AVICEL® was not properly identified. The specification has been amended to identify the trademark. She also indicated that the application lacks an abstract. An abstract is provided herewith.

Claims 14-15 were rejected under 35 USC § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The Examiner indicated that the claims lack active positive steps as required under U.S. practice for method claims. Claims 14 and 15 have been canceled. The subject matter has been incorporated into new claim 17, which recites active steps. It is respectfully submitted that claim 17 is free of the rejection


Claims 1-4, 6-8, and 10-15 have been rejected under 35 USC § 102(e) as being anticipated by Barsig et al. It is respectfully submitted that Barsig et al. do not teach or suggest the presently claimed combination of DFHO and loteprednol. Reconsideration and withdrawal of the rejection are respectfully requested.

Claims 1, 3, 5, 6, 8 and 9 have been rejected under 35 USC § 102(b) as being anticipated by Keller et al. It is respectfully submitted that Keller et al. do not teach or suggest the presently claimed combination of DFHO and loteprednol. Reconsideration and withdrawal of the rejection are respectfully requested.

All objections and rejections having been addressed, it is respectfully submitted that the application is in condition for allowance, and Notice to that effect is respectfully requested.

Respectfully submitted,

Date: 7/16/07

  
\_\_\_\_\_  
Ann S. Hobbs, Ph.D.  
Registration No. 36,830  
VENABLE LLP  
P.O. Box 34385  
Washington, D.C. 20043-9998

Telephone: (202) 344-4000  
Telefax: (202) 344-8300